Skip to main content
Clinical Trials/CTRI/2020/07/026839
CTRI/2020/07/026839CompletedPhase 3

A randomised double blind trial to evaluate the activity of SSV Formulation for management of SARS-CoV-2 Infection (COVID-19)

Shreepad Shree Vallabh SSV Phytopharmaceuticals0 sites200 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Enrollment
200

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • Quarantine/non hospitalized or hospitalized and fulfils WHO case definition, including a positive RT-PCR confirmed COVID-19 illness.
  • Age more than 18 & less than 65 years of either sex.
  • Mild to Moderately COVID-19 disease (NEWS score less than or equal to 8).
  • Patients with oxygen saturation (SpO2) less than 95%.
  • Respiratory rate is more than 20/min.
  • Pulse rate more than 90/min.
  • Imaging evidence of lung infection in the form of Reticulonodular opacities, ground-glass opacities and consolidation.

Exclusion Criteria

  • Pregnant women.
  • Breastfeeding women.
  • Requiring ICU admission at screening.
  • Patients above 65 years of age and below 18 Years.
  • Past History of MI, Epileptic episodes.
  • Any other co-morbidity (uncontrolled diabetes, severe hypertension from subject history) which is at critical stage at screening.
  • Asymptomatic patients.
  • Patients unwilling for informed consent.
  • Patients with prolonged QTc interval on ECG.
  • In the opinion of the clinical team, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments.
  • Participant with any immunosuppressive condition or hematological disease.
  • Participation in any other A.S.U and H protocol.

Investigators

Sponsor
Shreepad Shree Vallabh SSV Phytopharmaceuticals

Similar Trials